AU3456099A - Methods and compositions for eliciting an immune response to a telomerase antigen - Google Patents

Methods and compositions for eliciting an immune response to a telomerase antigen

Info

Publication number
AU3456099A
AU3456099A AU34560/99A AU3456099A AU3456099A AU 3456099 A AU3456099 A AU 3456099A AU 34560/99 A AU34560/99 A AU 34560/99A AU 3456099 A AU3456099 A AU 3456099A AU 3456099 A AU3456099 A AU 3456099A
Authority
AU
Australia
Prior art keywords
eliciting
compositions
methods
immune response
telomerase antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34560/99A
Other languages
English (en)
Inventor
Federico C.A. Gaeta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU3456099A publication Critical patent/AU3456099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU34560/99A 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen Abandoned AU3456099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11200698P 1998-03-31 1998-03-31
US60112006 1998-03-31
PCT/US1999/006898 WO1999050392A1 (en) 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen

Publications (1)

Publication Number Publication Date
AU3456099A true AU3456099A (en) 1999-10-18

Family

ID=22341634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34560/99A Abandoned AU3456099A (en) 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen

Country Status (6)

Country Link
US (1) US6440735B1 (enExample)
EP (1) EP1068296B1 (enExample)
JP (3) JP2002509716A (enExample)
AU (1) AU3456099A (enExample)
CA (1) CA2347067C (enExample)
WO (1) WO1999050392A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6808880B2 (en) * 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6444650B1 (en) * 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
CN102021153B (zh) 1996-10-01 2016-05-25 杰龙公司 人类的端粒酶催化亚单位
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
CA2344972A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) * 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN101068574B (zh) 2004-07-20 2012-07-18 伊索格尼斯股份有限公司 与自身抗原有关的自身免疫和疾病的特异性抑制
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
JPWO2006025526A1 (ja) * 2004-09-03 2008-05-08 株式会社医学生物学研究所 Ｃｔｌ誘導能を獲得した樹状細胞の製造方法
EP1801230A4 (en) * 2004-09-03 2008-03-05 Medical & Biol Lab Co Ltd METHOD FOR SELECTING LIGHT AS AN ANTIGEN PROTEINS PRESENTED ON DENTRIC CELLS
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
IL316252A (en) 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
RU2309753C1 (ru) * 2006-05-05 2007-11-10 ЗАО "РеМеТэкс" Комбинированный клеточный трансплантат на основе лимфокинактивированных киллеров и дендритных клеток, способ его получения и способ лечения и профилактики онкологических, инфекционных заболеваний и иммунодефицитных состояний
EP3753576A1 (en) 2006-09-26 2020-12-23 Genmab A/S Combination treatment of cd38-expressing tumors
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2010096693A2 (en) * 2009-02-19 2010-08-26 Mayo Foundation For Medical Education And Research Methods and materials for generating t cells
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
ES2751092T3 (es) 2010-02-16 2020-03-30 Ultimovacs Asa Polipéptidos
DK3904391T3 (en) 2010-03-10 2024-10-14 Genmab As Monoclonal antibodies against c-met
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
PT2580243T (pt) 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
HUE035599T2 (en) 2010-06-15 2018-05-28 Genmab As Human antibody drug conjugates against tissue factor
US8679474B2 (en) * 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
EP4520771A3 (en) 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
TWI571513B (zh) 2011-09-28 2017-02-21 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
EP2929013B1 (en) 2012-12-06 2020-02-05 Stembios Technologies, Inc. Lgr5+ somatic stem cells
EP2746769A1 (en) 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
WO2016089610A1 (en) 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
US20190167722A1 (en) * 2016-08-02 2019-06-06 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
WO2018156434A1 (en) 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Tim3-binding chimeric antigen receptors
JP7141725B2 (ja) 2017-07-07 2022-09-26 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 変異ｃｄ２８共刺激ドメインを有するキメラ抗原受容体
EP3737391A4 (en) 2018-01-08 2022-03-23 H. Lee Moffitt Cancer Center & Research Institute, Inc. COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS
CN111867613A (zh) 2018-01-09 2020-10-30 H·李·莫菲特癌症中心和研究所公司 靶向表达clec12a的癌症的组合物和方法
EP4069245A1 (en) 2019-12-02 2022-10-12 Celgene Corporation Therapy for the treatment of cancer
CA3172894A1 (en) 2020-02-27 2021-09-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Tumor-infiltrating lymphocytes with enhanced tumor reactivity
CA3175491A1 (en) 2020-05-05 2021-11-11 David DILILLO Car comprising cd28 zeta and cd3 zeta
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0147689B1 (en) 1983-12-05 1990-09-19 Asahi Kasei Kogyo Kabushiki Kaisha A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process
US6004807A (en) 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
CA2133409C (en) 1992-04-01 2011-05-24 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5648215A (en) 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6077519A (en) 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
EP0692973A1 (en) 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
DE69435010T2 (de) * 1993-04-20 2008-04-30 Hipler Partners Llp Verfahren und stoffe für die behandlung von individuen, die infiziert sind mit intrazellulär infektiösen agentien
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
DK0765386T3 (en) 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
JP3680219B2 (ja) 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5648219A (en) 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
US6010905A (en) 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US6015554A (en) 1995-06-07 2000-01-18 Systemix, Inc. Method of reconstituting human lymphoid and dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
AU7152296A (en) 1995-08-16 1997-03-12 Board Of Trustees Of The Leland Stanford Junior University Adult oligodendrocyte precursor cell compositions and methods
US5858777A (en) 1995-09-08 1999-01-12 Geron Corporation Methods and reagents for regulating telomere length and telomerase activity
AU1152397A (en) 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
DE69734974D1 (de) 1996-02-08 2006-02-02 Us Gov Health & Human Serv Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
WO1997040182A1 (de) 1996-04-19 1997-10-30 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US5747317A (en) 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
IL127912A0 (en) 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
WO1998007838A1 (en) 1996-08-21 1998-02-26 Mitsubishi Chemical Corporation Higher animal telomerase protein and gene encoding the same
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
CN102021153B (zh) * 1996-10-01 2016-05-25 杰龙公司 人类的端粒酶催化亚单位
CH689672A9 (de) 1996-10-01 2000-02-29 Geron Corp Katalytische Untereinheit menschlicher Telomerase.
US5812477A (en) 1996-10-03 1998-09-22 Micron Technology, Inc. Antifuse detection circuit
US6008004A (en) 1996-10-04 1999-12-28 Becton Dickinson & Company Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
JP2001503976A (ja) 1996-10-10 2001-03-27 デューク ユニヴァーシティ 樹状細胞の成熟を補助する胸腺微環境の生産法
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
AU5686898A (en) 1996-11-26 1998-06-22 Baylor College Of Medicine Identification of inhibitors that prevent access of telomerase to chrom osomal terminus
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
CA2286819A1 (en) 1997-04-17 1998-10-22 Flossie Wong-Staal Use of lentiviral vectors for antigen presentation in dendritic cells
AUPO723097A0 (en) 1997-06-06 1997-07-03 Australian National University, The A method for culturing cells
CA2294646A1 (en) 1997-06-20 1998-12-30 Bayer Aktiengesellschaft Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO1998059046A1 (en) 1997-06-25 1998-12-30 The Regents Of The University Of California Rice beta-glucanase enzymes and genes
KR100581990B1 (ko) 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
WO1999025812A1 (en) 1997-11-14 1999-05-27 Hemosol Inc. Method for the production and use of dendritic cells
JP2002509716A (ja) 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
WO1999051255A1 (en) 1998-04-06 1999-10-14 The Johns Hopkins University School Of Medicine Telomerase-associated proteins
NZ508936A (en) 1998-06-02 2005-01-28 Dendreon Corp Method for preparation and in vivo administration of antigen presenting cell composition
US6277613B1 (en) 1998-06-10 2001-08-21 The Rockefeller University TRF1 binding protein, methods of use thereof
EP1085892A4 (en) 1998-06-12 2002-07-17 Sloan Kettering Inst Cancer VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6482405B1 (en) 1998-09-15 2002-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
CA2344972A1 (en) 1998-10-29 2000-05-11 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including htert
GB9824306D0 (en) 1998-11-05 1998-12-30 Isis Innovation Method for producing dendritic dells
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine

Also Published As

Publication number Publication date
US6440735B1 (en) 2002-08-27
CA2347067C (en) 2013-09-17
JP2006020648A (ja) 2006-01-26
EP1068296B1 (en) 2011-08-10
WO1999050392A1 (en) 1999-10-07
CA2347067A1 (en) 1999-10-07
EP1068296A1 (en) 2001-01-17
JP2007137889A (ja) 2007-06-07
JP2002509716A (ja) 2002-04-02
EP1068296A4 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU3456099A (en) Methods and compositions for eliciting an immune response to a telomerase antigen
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
IL122340A0 (en) Helicobacter pylori antigens and vaccine compositions
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
AU3760100A (en) Immunostimulatory nucleic acids and antigens
IL145891A0 (en) Methods and compositions for modulating an immune response
HUP9903770A3 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU2002242085A1 (en) Methods and compositions useful for stimulating an immune response
AU3159499A (en) Antigen preparation and use
AU1940301A (en) Tick antigens and compositions and methods comprising them
AU2002215014A1 (en) Method and device for the preparation of fuels
AU7968398A (en) Compositions, devices, kit and method for modulating immune response
AU2001261005A1 (en) Immune mediators and related methods
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU2003204353A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2273397A (en) Methods and compositions for modulating an immune response
AU1597001A (en) Compositions and methods for modifying an immune response against tropomyosin
CZ20011896A3 (cs) Imunogenní prostředek a protilátka
AU2002239441A1 (en) Methods and compositions for inducing cell-mediated immune responses
AU2001266845A1 (en) Modulation of immune response and methods based thereon
AU7358098A (en) Radioisotope concentrator methods and compositions
AU8513698A (en) Methods and compositions for designing vaccines
AU2002248646A1 (en) Compositions and methods for modulating an immune response
GB2351905B (en) Eliciting improved immune responses
AU6200799A (en) Improving immune function

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase